Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC. This study focused on EGFR exon 20-positive lung cancer, which is a small subset of ...
Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results